Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
European Journal of Nuclear Medicine and Molecular Imaging
Published in: European Journal of Nuclear Medicine and Molecular Imaging 2/2017

01-02-2017 | Editorial

Radioiodine – the success story of Nuclear Medicine

75th Anniversary of the first use of Iodine-131 in humans

Author: V. Ralph McCready

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 2/2017

Login to get access

Excerpt

This year marks the 75th anniversary since Saul Hertz first administered radioiodine (I-130–I-131) to a patient on January 1st 1941 in the Massachusetts General Hospital as a treatment for hyperthyroidism. It followed his previous studies on animal thyroid physiology with I-128 to discover how radioiodine could be administered to have a maximal radiation effect in hyperthyroidism. In May 1946, Hertz and Roberts published the follow-up of their series of 29 patients treated with radioactive iodine for hyperthyroidism [1]. …
Literature
1.
Hertz S, Roberts A. Radioactive iodine in the study of thyroid physiology; the use of radioactive iodine therapy in hyperthyroidism. J Am Med Assoc. 1946;131:81–6.CrossRef
2.
Mazzaferri E. A randomized trial of remnant ablation--in search of an impossible dream? J Clin Endocrinol Metab. 2004;89(8):3662–4.CrossRef
3.
Webb S. From the watching of shadows: the origins of radiological tomography. 1990.: Bristol New York: Adam Hilgey. 1990.
4.
Smithers DW. Some varied applications of radioactive isotopes to the localization and treatment of tumors. Acta Radiol. 1951;35(1):49–61.CrossRef
5.
Siegel E. The beginnings of radioiodine therapy of metastatic thyroid carcinoma: a memoir of Samuel M. Seidlin, M. D. (1895–1955) and his celebrated patient. Cancer Biother Radiopharm. 1999;14(2):71–9.CrossRef
6.
Luster M, Clarke SE, Dietlein M, Lassmann M, Lind P, Oyen WJ, et al. Guidelines for radioiodine therapy of differentiated thyroid cancer. Eur J Nucl Med Mol Imaging. 2008;35(10):1941–59.CrossRef
7.
Mallick U, Harmer C, Yap B, Wadsley J, Clarke S, Moss L, et al. Ablation with low-dose radioiodine and thyrotropin alfa in thyroid cancer. N Engl J Med. 2012;366(18):1674–85.CrossRef
8.
Comtois R, Theriault C, Del VP. Assessment of the efficacy of iodine-131 for thyroid ablation. J Nucl Med. 1993;34(11):1927–30.
9.
Welsh L, Powell C, Pratt B, Harrington K, Nutting C, Harmer C, et al. Long-term outcomes following low-dose radioiodide ablation for differentiated thyroid cancer. J Clin Endocrinol Metab. 2013;98(5):1819–25.CrossRef
10.
Iyer NG, Morris LG, Tuttle RM, Shaha AR, Ganly I. Rising incidence of second cancers in patients with low-risk (T1N0) thyroid cancer who receive radioactive iodine therapy. Cancer. 2011;117(19):4439–46.CrossRef
11.
Hirsch D, Shohat T, Gorshtein A, Robenshtok E, Shimon I, Benbassat C. Incidence of Nonthyroidal Primary Malignancy and the Association with (131)I Treatment in Patients with Differentiated Thyroid Cancer. Thyroid. 2016;26(8):1110–6.CrossRef
12.
Durante C, Haddy N, Baudin E, Leboulleux S, Hartl D, Travagli JP, et al. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J Clin Endocrinol Metab. 2006;91(8):2892–9.CrossRef
13.
Mallick U, Harmer C, Hackshaw A, Moss L. Iodine or Not (IoN) for low-risk differentiated thyroid cancer: the next UK National Cancer Research Network randomised trial following HiLo. Clin Oncol (R Coll Radiol). 2012;24(3):159–61.CrossRef
14.
Flux GD, Haq M, Chittenden SJ, Buckley S, Hindorf C, Newbold K, et al. A dose-effect correlation for radioiodine ablation in differentiated thyroid cancer. Eur J Nucl Med Mol Imaging. 2010;37(2):270–5.CrossRef
15.
Wierts R, Brans B, Havekes B, Kemerink GJ, Halders SG, Schaper NN, et al. Dose–response Relationship in Differentiated Thyroid Cancer Patients Undergoing Radioiodine Treatment Assessed by Means of 124I PET/CT. J Nucl Med. 2016;57(7):1027–32.CrossRef
16.
Jentzen W, Verschure F, van ZA, van de KR, Wierts R, Schmitz J, et al. Response Assessment of Bone Metastases from Differentiated Thyroid Cancer Patients in the Initial Radioiodine Treatment Using Iodine-124 PET Imaging. J Nucl Med. 2016.
17.
Franzius C, Dietlein M, Biermann M, Fruhwald M, Linden T, Bucsky P, et al. Procedure guideline for radioiodine therapy and 131iodine whole-body scintigraphy in paediatric patients with differentiated thyroid cancer. Nuklearmedizin. 2007;46(5):224–31.CrossRef
18.
Wang J, Qin L. Radioiodine therapy versus antithyroid drugs in Graves’ disease: a meta-analysis of randomized controlled trials. Br J Radiol. 2016:20160418.
19.
Ross DS, Burch HB, Cooper DS, Greenlee MC, Laurberg P, Maia AL, et al. 2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and other causes of Thyrotoxicosis. Thyroid. 2016.
20.
Stokkel MP, Handkiewicz JD, Lassmann M, Dietlein M, Luster M. EANM procedure guidelines for therapy of benign thyroid disease. Eur J Nucl Med Mol Imaging. 2010;37(11):2218–28.CrossRef
21.
Reiners C, Schneider P. Radioiodine therapy of thyroid autonomy. Eur J Nucl Med Mol Imaging. 2002;29 Suppl 2:S471–S8.CrossRef
22.
Aktas GE, Turoglu HT, Erdil TY, Inanir S, Dede F. Long-Term Results of Fixed High-Dose I-131 Treatment for Toxic Nodular Goiter: Higher Euthyroidism Rates in Geriatric Patients. Mol Imaging Radionucl Ther. 2015;24(3):94–9.CrossRef
23.
McCready VR, Dizdarevic S, Aplin M. Interventional nuclear medicine. Eur J Nucl Med Mol Imaging. 2013;40(7):1044–6.CrossRef
24.
Happel C, Korkusuz H, Koch DA, Grunwald F, Kranert WT. Combination of ultrasound guided percutaneous microwave ablation and radioiodine therapy in benign thyroid diseases. A suitable method to reduce the 131I activity and hospitalization time? Nuklearmedizin. 2015;54(3):118–24.CrossRef
25.
Sung JY, Baek JH, Jung SL, Kim JH, Kim KS, Lee D, et al. Radiofrequency ablation for autonomously functioning thyroid nodules: a multicenter study. Thyroid. 2015;25(1):112–7.CrossRef
Metadata
Title
Radioiodine – the success story of Nuclear Medicine
75th Anniversary of the first use of Iodine-131 in humans
Author
V. Ralph McCready
Publication date
01-02-2017
Publisher
Springer Berlin Heidelberg
Published in
European Journal of Nuclear Medicine and Molecular Imaging / Issue 2/2017
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-016-3548-5

Other articles of this Issue 2/2017

European Journal of Nuclear Medicine and Molecular Imaging 2/2017 Go to the issue

Original Article

Recurrent bladder carcinoma: clinical and prognostic role of 18 F-FDG PET/CT

Image of the Month

Brain perfusion SPECT for brain death assessment

Original Article

The role of FDG PET/CT in patients treated with neoadjuvant chemotherapy for localized bone sarcomas

Original Article

Clinical values of left ventricular mechanical dyssynchrony assessment by gated myocardial perfusion SPECT in patients with acute myocardial infarction and multivessel disease

Original Article

Lymphocyte function following radium-223 therapy in patients with metastasized, castration-resistant prostate cancer

Review Article

Nuclear medicine imaging of multiple myeloma, particularly in the relapsed setting